Advances in the pathophysiology and treatment of heparin-induced thrombocytopenia

Current Opinion in Hematology

Volumn 21, Issue 5, 2014, Pages 380-387

  McKenzie, Steven E ^a   Sachais, Bruce S ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

FcgRIIa; heparin; heparin induced thrombocytopenia; immune mediated thrombocytopenia and thrombosis; platelet factor 4

Indexed keywords

FC RECEPTOR IIA; HEPARIN; IMMUNOGLOBULIN G ANTIBODY; THROMBOCYTE FACTOR 4; ANTICOAGULANT AGENT; THROMBIN;

ANTIGEN PRESENTING CELL; ARTICLE; BLEEDING; ENDOTHELIUM CELL; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; MONOCYTE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOSIS; CHEMICALLY INDUCED; METABOLISM; THROMBOCYTOPENIA;

ANTICOAGULANTS; HEPARIN; HUMANS; PLATELET ACTIVATION; PLATELET FACTOR 4; THROMBIN; THROMBOCYTOPENIA;

EID: 84906101415     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0000000000000066     Document Type: Article

References (69)

1. Potschke C, Selleng S, Broker BM, Greinacher A. Heparin-induced thrombocytopenia: Further evidence for a unique immune response. Blood 2012; 120:4238-4245
2. Suvarna S, Espinasse B, Qi R, et al. Determinants of PF4/heparin immunogenicity. Blood 2007; 110:4253-4260
3. Suvarna S, Qi R, Arepally GM. Optimization of a murine immunization model for study of PF4/heparin antibodies. J Thromb Haemost 2009; 7:857-864
4. Greinacher A, Holtfreter B, Krauel K, et al. Association of natural antiplatelet factor 4/heparin antibodies with periodontal disease. Blood 2011; 118:1395-1401
5. Krauel K, Potschke C, Weber C, et al. Platelet factor 4 binds to bacteria, [corrected] inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia. Blood 2011; 117:1370-1378
6. Krauel K, Weber C, Brandt S, et al. Platelet factor 4 binding to lipid A of Gram-negative bacteria exposes PF4/heparin-like epitopes. Blood 2012; 120:3345-3352
7. Arman M, Krauel K, Tilley DO, et al. Amplification of bacteria-induced platelet activation is triggered by FcgammaRIIA, integrin alphaIIbbeta3 and platelet factor 4. Blood 2014; 123:3155-3166
8. Pongas G, Dasgupta SK, Thiagarajan P. Antiplatelet factor 4/heparin antibodies in patients with Gram negative bacteremia. Thromb Res 2013; 132:217-220.
9. Jaax ME, Krauel K, Marschall T, et al. Complex formation with nucleic acids and aptamers alters the antigenic properties of platelet factor 4. Blood 2013; 122:272-281
10. Chong BH, Chong JJ. HIT: Nucleic acid masquerading as heparin. Blood 2013; 122:156-158
11. Brandt S, Krauel K, Gottschalk KE, et al. Characterisation of the conformational changes in platelet factor 4 induced by polyanions: Towards in vitro prediction of antigenicity. Thromb Haemost 2014; 112:; http://dx.doi.org/ 10.1160/TH13-08-0634
12. Zheng Y, Wang AW, Yu M, et al. B-cell tolerance regulates production of antibodies causing heparin-induced thrombocytopenia. Blood 2014; 123:931-934
13. Zheng Y, Yu M, Podd A, et al. Critical role for mouse marginal zone B cells in PF4/heparin antibody production. Blood 2013; 121:3484-3492
14. Li ZQ, Liu W, Park KS, et al. Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody. Blood 2002; 99:1230-1236
15. Ziporen L, Li ZQ, Park KS, et al. Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia. Blood 1998; 92:3250-3259
16. Greinacher A, Gopinadhan M, Gunther JU, et al. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies. Arterioscler Thromb Vasc Biol 2006; 26:2386-2393
17. Rauova L, Poncz M, McKenzie SE, et al. Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood 2005; 105:131-138
18. Sachais BS, Litvinov RI, Yarovoi SV, et al. Dynamic antibody-binding properties in the pathogenesis of HIT. Blood 2012; 120:1137-1142
19. Litvinov RI, Yarovoi SV, Rauova L, et al. Distinct specificity and singlemolecule kinetics characterize the interaction of pathogenic and nonpathogenic antibodies against platelet factor 4-heparin complexes with platelet factor 4. J Biol Chem 2013; 288:33060-33070
20. Block S, Greinacher A, Helm CA, Delcea M. Characterization of bonds formed between platelet factor 4 and negatively charged drugs using single molecule force spectroscopy. Soft Matter 2014; 10:2775-2784.
21. Asada R, Wanaka K, Walenga J, et al. Murine monoclonal antibody to platelet factor 4/heparin complexes as a potential reference standard for platelet activation assays in heparin-induced thrombocytopenia. Clin Appl Thromb Hemost 2013; 19:37-41
22. Chudasama SL, Espinasse B, Hwang F, et al. Heparin modifies the immunogenicity of positively charged proteins. Blood 2010; 116:6046-6053
23. Lee GM, Arepally GM. Heparin-induced thrombocytopenia. Hematology Am Soc Hematol Educ Program 2013; 2013:668-674
24. Bakchoul T, Zollner H, Amiral J, et al. Antiprotamine-heparin antibodies: Incidence, clinical relevance, and pathogenesis. Blood 2013; 121:2821-2827
25. Pouplard C, Leroux D, Rollin J, et al. Incidence of antibodies to protamine sulfate/heparin complexes in cardiac surgery patients and impact on platelet activation and clinical outcome. Thromb Haemost 2013; 109:1141-1147
26. Lee GM, Welsby IJ, Phillips-Bute B, et al. High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass. Blood 2013; 121:2828-2835
27. Warkentin TE, Hayward CP, Boshkov LK, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994; 84:3691-3699
28. Hughes M, Hayward CP, Warkentin TE, et al. Morphological analysis of microparticle generation in heparin-induced thrombocytopenia. Blood 2000; 96:188-194
29. Andre P, McKenzie SE, Bergmeier W. The parallel signaling pathways of phosphatidylserine (PS) exposure downstream of platelet FcgRIIa. Blood 2013; 122:3514
30. Reilly MP, Sinha U, Andre P, et al. PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model. Blood 2011; 117:2241-2246
31. Stolla M, Stefanini L, Andre P, et al. CalDAG-GEFI deficiency protects mice in a novel model of Fcgamma RIIA-mediated thrombosis and thrombocytopenia. Blood 2011; 118:1113-1120
32. Yeung J, Apopa PL, Vesci J, et al. 12-Lipoxygenase activity plays an important role in PAR4 and GPVI-mediated platelet reactivity. Thromb Haemost 2013; 110:569-581
33. Zhi H, Rauova L, Hayes V, et al. Cooperative integrin/ITAM signaling in platelets enhances thrombus formation in vitro and in vivo. Blood 2013; 121:1858-1867
34. Prechel MM, Walenga JM. Emphasis on the role of PF4 in the incidence, pathophysiology and treatment of heparin induced thrombocytopenia. Thromb J 2013; 11:7
35. Rollin J, Pouplard C, Gratacap MP, et al. Polymorphisms of protein tyrosine phosphatase CD148 influence FcgammaRIIA-dependent platelet activation and the risk of heparin-induced thrombocytopenia. Blood 2012; 120:1309-1316
36. Scarparo P, Lombardi AM, Duner E, et al. Heparin-induced thrombocytopenia: The role of platelets genetic polymorphisms. Platelets 2013; 24:362-368
37. Abraham S, Andre P, Zhou Y, et al. Differential expression of microRNAs accompanies differential reactivity via platelet FcgammaRIIa in humans and transgenic mice. Blood 2012; 120:2165a.
38. Pouplard C, Iochmann S, Renard B, et al. Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Blood 2001; 97:3300-3302
39. Arepally GM, Mayer IM. Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8. Blood 2001; 98:1252-1254
40. Kasthuri RS, Glover SL, Jonas W, et al. PF4/heparin-Antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcgammaRI. Blood 2012; 119:5285-5293
41. Tutwiler V, Ahn HS, Cines DB, et al. Microfluidic and flow cytometric studies support a central role of monocytes and coat platelets in the prothrombotic state in heparin-induced thrombocytopenia (HIT). Blood 2011; 118:531a.
42. Tutwiler V, Ahn HS, Fuentes R, et al. Fibrin generation in heparin-induced thrombocytopenia (HIT): Pathomechanistic background for novel therapy and prophylaxis. Blood 2012; 120:635a.
43. Rauova L, Hirsch JD, Greene TK, et al. Monocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopenia. Blood 2010; 116:5021-5031
44. Coventry DA, Webster NR. Heparin-induced thrombocytopenia and the health economic analysis of argatroban. Br J Anaesth 2014; 112:964-967
45. Linkins LA, Dans AL, Moores LK, et al., American College of Chest Physicians. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e495S-e530S.
46. Kelton JG, Arnold DM, Bates SM. Nonheparin anticoagulants for heparininduced thrombocytopenia. N Engl J Med 2013; 368:737-744
47. Schindewolf M, Steindl J, Beyer-Westendorf J, et al. Frequent off-label use of fondaparinux in patients with suspected acute heparin-induced thrombocytopenia (HIT) - findings from the GerHIT Multicentre Registry Study. Thromb Res 2014; http://dx.doi.org/10.1016/j.thromres.2014.03.029
48. Ratuapli SK, Bobba B, Zafar H. Heparin-induced thrombocytopenia in a patient treated with fondaparinux. Clin Adv Hematol Oncol 2010; 8:61-65
49. Bhatt VR, Aryal MR, Shrestha R, Armitage JO. Fondaparinux-Associated heparin-induced thrombocytopenia. Eur J Haematol 2013; 91:437-441
50. Tanhehco YC, Rux AH, Sachais BS. Low-density lipoprotein apheresis reduces platelet factor 4 on the surface of platelets: A possible protective mechanism against heparin-induced thrombocytopenia and thrombosis. Transfusion 2011; 51:1022-1029
51. Tanhehco YC, Cuker A, Rudnick M, Sachais BS. Investigation of a potential protective mechanism against heparin-induced thrombocytopenia in patients on chronic intermittent hemodialysis. Thromb Res 2013; 131:244-248
52. Pierce W, Mazur J, Greenberg C, et al. Evaluation of heparin-induced thrombocytopenia (HIT) laboratory testing and the 4Ts scoring system in the intensive care unit. Ann Clin Lab Sci 2013; 43:429-435
53. Cegarra-Sanmartin V, Gonzalez-Rodriguez R, Paniagua-Iglesias P, et al. Fondaparinux as a safe alternative for managing heparin-induced thrombocytopenia in postoperative cardiac surgery patients. J Cardiothorac Vasc Anesth 2014; http://dx.doi.org/10.1053/j.jvca.2013.09.008
54. Beiras-Fernandez A, Kanzler I, Michel S, et al. Platelet factor 4-positive thrombi adhering to the ventricles of a ventricular assist device in patients with heparin-induced thrombocytopenia type II. Transplant Proc 2013; 45:2013-2016
55. Matsuo T, Wanaka K, Walenga JM. Evaluation of circuit and AV fistula clotting and detection of anti-PF4/heparin complex antibodies in hemodialysis patients suspected of having heparin-induced thrombocytopenia. Clin Appl Thromb Hemost 2013; 19:73-78
56. Zhao D, Sun X, Yao L, et al. The clinical significance and risk factors of antiplatelet factor 4/heparin antibody on maintenance hemodialysis patients: A two-year prospective follow-up. PLoS One 2013; 8:e62239
57. Althaus K, Hron G, Strobel U, et al. Evaluation of automated immunoassays in the diagnosis of heparin induced thrombocytopenia. Thromb Res 2013; 131:e85-e90
58. Raschke RA, Curry SC, Warkentin TE, Gerkin RD. Improving clinical interpretation of the antiplatelet factor 4/heparin enzyme-linked immunosorbent assay for the diagnosis of heparin-induced thrombocytopenia through the use of receiver operating characteristic analysis, stratumspecific likelihood ratios, and Bayes theorem. Chest 2013; 144:1269-1275
59. Garritsen HS, Probst-Kepper M, Legath N, et al. High sensitivity and specificity of a new functional flow cytometry assay for clinically significant heparininduced thrombocytopenia antibodies. Int J Lab Hematol 2014; 36:135-143
60. Solano C, Mutsando H, Self M, et al. Using HitAlert flow cytometry to detect heparin-induced thrombocytopenia antibodies in a tertiary care hospital. Blood Coagul Fibrinolysis 2013; 24:365-370
61. Galea V, Khaterchi A, Robert F, et al. Heparin-induced multiple electrode aggregometry is a promising and useful functional tool for heparin-induced thrombocytopenia diagnosis: Confirmation in a prospective study. Platelets 2013; 24:441-447
62. Cuker A, Rux AH, Hinds JL, et al. Novel diagnostic assays for heparin-induced thrombocytopenia. Blood 2013; 121:3727-3732
63. Gardiner EE, Karunakaran D, Arthur JF, et al. Dual ITAM-mediated proteolytic pathways for irreversible inactivation of platelet receptors: De-ITAM-izing FcgammaRIIa. Blood 2008; 111:165-174
64. Nazi I, Arnold DM, Smith JW, et al. FcgammaRIIa proteolysis as a diagnostic biomarker for heparin-induced thrombocytopenia. J Thromb Haemost 2013; 11:1146-1153
65. Medvedev N, Palankar R, Krauel K, et al. Micropatterned array to assess the interaction of single platelets with platelet factor 4-heparin-IgG complexes. Thromb Haemost 2014; 111:862-872
66. Joglekar MV, Quintana Diez PM, Marcus S, et al. Disruption of PF4/H multimolecular complex formation with a minimally anticoagulant heparin (ODSH). Thromb Haemost 2012; 107:717-725
67. Krauel K, Hackbarth C, Furll B, Greinacher A. Heparin-induced thrombocytopenia: In vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies. Blood 2012; 119:1248-1255
68. Rao NV, Argyle B, Xu X, et al. Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands. Am J Physiol Cell Physiol 2010; 299:C97-C110
69. Lhermusier T, Van Rottem J, Garcia C, et al. The Syk-kinase inhibitor R406 impairs platelet activation and monocyte tissue factor expression triggered by heparin-PF4 complex directed antibodies. J Thromb Haemost 2011; 9:2067-2076.